Curative Biotechnology, Inc. (CUBT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Curative Biotechnology, Inc. (CUBT) trades at $1.00 with AI Score 42/100 (Grade C). Curative Biotechnology, Inc. Market cap: $6.82M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CUBT: CUBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CUBT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CUBT: the 1 perspectives are evenly split.
How is this calculated? →Curative Biotechnology, Inc. (CUBT) Healthcare & Pipeline Overview
Curative Biotechnology, Inc. is a development-stage biomedical firm specializing in pharmaceutical product research and development within the biotechnology sector. The company focuses on a diverse pipeline targeting infectious diseases, oncology, and vision-impairing conditions, leveraging an immunotherapy platform and strategic co-development partnerships to advance its therapeutic candidates.
What Is the Investment Thesis for CUBT?
Curative Biotechnology, Inc. represents a development-stage biotechnology company with a pipeline focused on high-impact therapeutic areas, including infectious diseases, oncology, and degenerative eye conditions. The company's primary value drivers are its key pipeline assets: IMT504, an immunotherapy for rabies and vaccine enhancement; CUBT906, a targeted oncology monoclonal antibody; and a reformulated Metformin for eye disorders. A significant growth catalyst is the ongoing licensing and co-development partnership with Mid-Atlantic BioTherapeutics for IMT504, which could accelerate clinical progress and potential market entry. Future clinical trial results and regulatory approvals for these candidates will be critical milestones determining the company's valuation and trajectory. As a small-cap, development-stage entity with a market capitalization of $6.82M and trading on the OTC market, CUBT carries inherent risks related to funding, clinical success, and liquidity. Investors should monitor progress through clinical phases, potential for additional partnerships, and the company’s ability to secure necessary capital to advance its research and development efforts towards commercialization.
Based on FMP financials and quantitative analysis
CUBT Key Highlights
- Market Capitalization: $0.01 billion, indicating its status as a micro-cap development-stage biotechnology company.
- Beta: 1.39, suggesting higher volatility compared to the broader market, typical for early-stage biotech firms.
- Employees: 4, reflecting a lean operational structure focused on research and development.
- Dividend Yield: None, as the company is in a development phase and not distributing profits.
- Development Stage: Operations are primarily focused on R&D, with no commercialized products generating revenue yet.
Who Are CUBT's Competitors?
CUBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CUBT's Key Strengths?
- Diverse pipeline targeting critical therapeutic areas: infectious diseases, oncology, and degenerative eye conditions.
- Key pipeline assets like IMT504 (immunotherapy for rabies) and CUBT906 (targeted cancer antibody) address significant unmet medical needs.
- Strategic licensing and co-development partnership with Mid-Atlantic BioTherapeutics for IMT504.
- Focus on innovative approaches such as immunotherapy and targeted drug delivery.
What Are CUBT's Weaknesses?
- Operates as a development-stage company with no commercialized products or revenue generation.
- Small market capitalization ($0.01B) and only 4 employees, indicating limited resources.
- Trades on the OTC market, which typically implies lower liquidity and higher volatility.
- Disclosure status is unknown, potentially limiting investor access to financial and operational information.
What Could Drive CUBT Stock Higher?
- Positive clinical trial results for IMT504 in rabies treatment or as a vaccine enhancer, which could validate its therapeutic potential and attract further investment.
- Achievement of key development milestones within the licensing and co-development partnership with Mid-Atlantic BioTherapeutics for IMT504.
- Initiation of clinical trials for CUBT906 in oncology or for the reformulated Metformin in degenerative eye disorders, signaling pipeline advancement.
- Securing additional funding rounds or strategic partnerships to support the continued research and development of its pipeline assets.
- Any updates on the company's disclosure status, moving towards greater transparency, could improve investor confidence and market perception.
What Are the Key Risks for CUBT?
- Financial-distress signal — its Altman Z-Score of -37.51 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High R&D costs and the need for significant capital raises, potentially leading to shareholder dilution, given its development-stage nature.
- Clinical trial failures or unexpected adverse events for any of its pipeline candidates, which could halt development and diminish company value.
- Regulatory hurdles and delays in obtaining necessary approvals from health authorities, extending time-to-market and increasing costs.
- Significant liquidity and volatility risks associated with trading on the 'OTC Other' market, making it difficult for investors to trade shares efficiently.
- Intense competition from larger, more established pharmaceutical companies with greater resources and existing market presence in its target therapeutic areas.
What Are the Growth Opportunities for CUBT?
- Growth opportunity 1: Advancement of IMT504 for Rabies Treatment. The global rabies vaccine market was valued at approximately $1.1 billion in 2023 and is projected to grow. IMT504, an innovative immunotherapy, targets both rabies treatment and vaccine enhancement. Successful progression through clinical trials and eventual regulatory approval for this candidate could unlock a significant market opportunity, particularly in regions with high rabies incidence and for post-exposure prophylaxis. The co-development partnership with Mid-Atlantic BioTherapeutics further de-risks and accelerates its development timeline, potentially leading to commercialization within the next 5-7 years.
- Growth opportunity 2: Development of CUBT906 for Oncology. The global oncology therapeutics market is a multi-hundred-billion-dollar industry, with targeted therapies and immunotherapies being key growth drivers. CUBT906, a fully humanized CD56 monoclonal antibody delivering a pyrrolobenzodiazepine dimer to tumor cells, represents a precision medicine approach to cancer treatment. Successful clinical development and demonstration of efficacy and safety could position CUBT906 to address unmet needs in specific cancer types, offering a substantial revenue stream within an estimated 7-10 year timeframe, contingent on trial success and regulatory milestones.
- Growth opportunity 3: Reformulated Metformin for Degenerative Eye Disorders. The market for ophthalmic drugs, particularly for degenerative conditions like macular degeneration or diabetic retinopathy, is substantial and growing, estimated at over $40 billion annually. Curative Biotechnology's advancement of a reformulated Metformin for these conditions taps into a large patient population. If clinical trials demonstrate improved efficacy or a better safety profile compared to existing treatments, this candidate could capture a meaningful share of the market, with potential commercialization within 5-8 years, offering a new therapeutic option.
- Growth opportunity 4: Leveraging the Mid-Atlantic BioTherapeutics Partnership. The licensing and co-development partnership for IMT504, specifically for advanced rabies and as a COVID-19 vaccine component, is a critical growth driver. This collaboration provides access to additional expertise, resources, and potentially accelerates the development timeline for IMT504. Successful achievement of milestones within this partnership, such as positive clinical data or expanded indications, could significantly enhance Curative Biotechnology's valuation and attract further strategic alliances, potentially within the next 3-5 years.
- Growth opportunity 5: Expansion of Pipeline through Strategic In-licensing or Acquisitions. As a development-stage company, future growth could be driven by strategically expanding its pipeline through in-licensing promising early-stage assets or acquiring complementary technologies. This approach could diversify its risk profile, broaden its therapeutic reach, and enhance its long-term growth prospects by adding new potential revenue streams. Identifying and integrating novel compounds or platforms that align with its current R&D focus in infectious diseases, oncology, or ophthalmology could create significant value over a 5-10 year horizon, contingent on capital availability and strategic execution.
What Opportunities Does CUBT Have?
- Successful progression of pipeline candidates through clinical trials and regulatory approvals.
- Expansion of the co-development partnership or formation of new strategic alliances for other pipeline assets.
- Potential to address large global markets for rabies treatment, various cancers, and degenerative eye disorders.
- Securing additional funding to accelerate R&D and expand the drug pipeline.
What Threats Does CUBT Face?
- High risk of clinical trial failures or delays, which are common in biotechnology development.
- Intense competition from larger, more established pharmaceutical and biotechnology companies.
- Significant capital requirements for R&D, with potential for dilution if new funding is raised through equity.
- Regulatory hurdles and the lengthy, costly approval processes for new pharmaceutical products.
What Are CUBT's Competitive Advantages?
- Proprietary pipeline of drug candidates, including novel immunotherapies and targeted cancer treatments, offering potential first-in-class or best-in-class therapies.
- Strategic co-development partnership with Mid-Atlantic BioTherapeutics, providing shared resources, expertise, and reduced development risk for IMT504.
- Specialized focus on high-impact therapeutic areas with significant unmet medical needs, such as advanced rabies and specific oncology targets.
- Intellectual property surrounding its drug candidates, once secured, would provide market exclusivity and protection against generic competition.
What Does CUBT Do?
Curative Biotechnology, Inc. is an emerging biomedical firm established in 1995, with its headquarters located in Boca Raton, Florida. Initially known as Connectyx Technologies Holdings Group, Inc., the company underwent a significant strategic pivot and rebranded to Curative Biotechnology, Inc. in November 2020, signaling its dedicated focus on pharmaceutical product development. The company's core operations revolve around extensive research and development efforts, concentrating on a diverse pipeline of therapeutic candidates aimed at addressing critical unmet medical needs. Its current R&D portfolio spans three major therapeutic areas: infectious diseases, oncology (cancer), and vision-impairing degenerative eye conditions. A key asset in its pipeline is IMT504, an innovative immunotherapy candidate being developed for rabies treatment and as a vaccine enhancer, demonstrating the company's commitment to addressing global health challenges. Another prominent candidate, CUBT906, represents an advanced approach in cancer therapy; it is a fully humanized CD56 monoclonal antibody designed to precisely deliver a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to inhibit their growth and prevent their spread. Furthermore, Curative Biotechnology is advancing a reformulated Metformin, exploring its potential in the management of degenerative eye disorders, which highlights its diversified approach to drug development. To accelerate the development of IMT504, particularly for advanced rabies and as a component of a COVID-19 vaccine, Curative Biotechnology has forged a strategic licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. This collaboration underscores the company's strategy to leverage external expertise and resources to advance its pipeline, positioning it as a focused player in the competitive biotechnology landscape.
What Products and Services Does CUBT Offer?
- Develop pharmaceutical products across various therapeutic areas, including infectious diseases, cancer, and degenerative eye conditions.
- Conduct research and development on innovative drug candidates like IMT504 for rabies treatment and vaccine enhancement.
- Advance CUBT906, a fully humanized CD56 monoclonal antibody, for targeted cancer therapy.
- Reformulate existing drugs, such as Metformin, for new applications in degenerative eye disorders.
- Engage in licensing and co-development partnerships to accelerate drug pipeline progress, specifically with Mid-Atlantic BioTherapeutics for IMT504.
- Focus on preclinical and clinical stage development of novel biomedical solutions.
How Does CUBT Make Money?
- Primarily operates as a research and development entity, investing in the discovery and preclinical/clinical development of drug candidates.
- Aims to generate future revenue through the successful commercialization of its proprietary pharmaceutical products, either independently or through partnerships.
- Leverages licensing and co-development agreements to share development costs, risks, and potentially future profits with partners.
- Relies on securing capital through equity financing or grants to fund its extensive R&D operations.
- Potential future revenue streams from royalties or direct sales upon regulatory approval and market launch of its pipeline assets.
What Industry Does CUBT Operate In?
Curative Biotechnology, Inc. operates within the highly specialized and capital-intensive biotechnology industry, a segment of the broader healthcare sector characterized by extensive research and development. This industry is driven by innovation in drug discovery and development, targeting a wide range of diseases. Market trends indicate a growing demand for novel therapies in oncology, infectious diseases, and rare conditions, with significant investment in immunotherapies and targeted drug delivery systems. Curative Biotechnology's focus on these areas, particularly with IMT504 and CUBT906, positions it within a competitive landscape dominated by both large pharmaceutical companies and numerous smaller, development-stage biotechs. Success in this industry is heavily reliant on clinical trial outcomes, regulatory approvals, and strategic partnerships. As a company with a small employee base and market capitalization, Curative Biotechnology's competitive positioning is currently defined by its pipeline's potential and its ability to secure funding and partnerships to advance its drug candidates through rigorous development phases.
Who Are CUBT's Key Customers?
- Currently, its primary 'customers' are research institutions and regulatory bodies as it progresses through clinical trials.
- Upon commercialization, target customers would include healthcare providers such as hospitals, clinics, and specialized medical centers.
- Ultimately, patients suffering from rabies, various cancers, and degenerative eye disorders would be the end-users of its therapeutic products.
- Pharmaceutical and biotechnology companies seeking licensing opportunities or co-development partners for specific therapeutic areas.
Company Profile
Curative Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palm Beach Gardens, US. The company is led by CEO I. Richard Garr. CUBT has traded publicly since 1998.
F-Score 1/9Financial Health
Curative Biotechnology, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -37.51 places it in the distress zone, a signal of elevated financial risk.
ROE 36%Key Financial Metrics
Return on equity for Curative Biotechnology, Inc. stands at 36.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -14.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -32.4%, the inverse of the P/E and a quick read on earnings relative to price.
CUBT Valuation & Market Position
With a $6.82M market cap, Curative Biotechnology, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CUBT's quantitative score of 42/100 is below the peer average of 76/100.
CUBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Curative Biotechnology has seen increased insider buying, suggesting confidence in the company's future prospects.
- Recent developments in their product pipeline have garnered positive attention from the community, indicating potential breakthroughs.
- Social sentiment has shifted positively, with discussions around their innovative approaches to biotech attracting interest.
- The company's focus on addressing urgent health needs resonates well with current market trends, enhancing its appeal to investors.
Bear Case
- Despite the positive sentiment, some analysts express concerns about the sustainability of recent gains without solid financial backing.
- Community discussions also highlight skepticism regarding the commercialization timeline of their products, which could affect investor confidence.
- There are ongoing regulatory challenges in the biotech sector that could hinder Curative's progress and impact market perception.
- The heightened competition in the biotech space raises questions about Curative's ability to differentiate itself and capture market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CUBT Latest News
No recent news available for CUBT.
CUBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CUBT.
Price Targets
Wall Street price target analysis for CUBT.
CUBT MoonshotScore
What does this score mean?
The MoonshotScore rates CUBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: I. Richard Garr
Chief Executive Officer
I. Richard Garr serves as the Chief Executive Officer of Curative Biotechnology, Inc., leading a lean team of four employees. His leadership is central to the company's strategic direction and operational focus within the biomedical sector. While specific details of his prior career history and educational background are not provided, his role at the helm of a development-stage biotechnology firm suggests a background in corporate leadership, potentially within the healthcare or life sciences industries, where strategic vision and resource management are paramount. His tenure has overseen the company's significant pivot into its current biotechnology focus.
Track Record: Under I. Richard Garr's leadership, Curative Biotechnology, Inc. has undergone a pivotal transformation, rebranding from Connectyx Technologies Holdings Group, Inc. in November 2020 to concentrate exclusively on pharmaceutical product development. He has been instrumental in shaping the company's current pipeline, which includes key assets like IMT504 and CUBT906. A notable achievement under his guidance is the establishment of a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc., crucial for advancing IMT504. His strategic decisions have positioned the company in critical therapeutic areas, despite its small operational footprint.
CUBT OTC Market Information
Curative Biotechnology, Inc. trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements of higher OTC tiers like OTCQX or OTCQB, or do not qualify for a listing on major exchanges like NYSE or NASDAQ. Companies on 'OTC Other' may have limited public information available and are not required to report to the SEC. This classification generally indicates a higher risk profile due to less stringent reporting standards compared to exchange-listed or even higher-tier OTC companies, making comprehensive due diligence more challenging for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: Unknown disclosure status means investors may lack critical financial and operational data.
- Low Liquidity: Trading on 'OTC Other' often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares.
- Price Volatility: Illiquidity and limited information can lead to significant and unpredictable price fluctuations.
- Regulatory Scrutiny: Companies on lower OTC tiers may be subject to less regulatory oversight, increasing potential for fraud or manipulation.
- Difficulty in Valuation: Lack of comprehensive and timely financial reports complicates fundamental analysis and accurate valuation.
- Verify the company's current financial statements and audit reports, if available, through alternative sources.
- Research any available corporate filings or news releases for updates on pipeline progress and partnerships.
- Investigate the background and track record of the management team beyond what is publicly stated.
- Assess the intellectual property portfolio and patent status for key drug candidates.
- Understand the regulatory pathway and clinical trial status for each pipeline asset.
- Evaluate the company's funding strategy and cash burn rate to determine future capital needs.
- Seek independent legal and financial advice regarding the risks associated with OTC 'Other' investments.
- Established in 1995, indicating a long operational history, albeit with a recent strategic pivot.
- Active research and development pipeline with specific drug candidates (IMT504, CUBT906, reformulated Metformin).
- Existence of a formal co-development partnership with Mid-Atlantic BioTherapeutics, Inc.
- Clear articulation of its focus on critical therapeutic areas within the biotechnology sector.
- Identified headquarters location in Boca Raton, Florida.
CUBT Healthcare Stock FAQ
What does Curative Biotechnology, Inc. do?
Curative Biotechnology, Inc. is a biomedical firm primarily engaged in the research and development of pharmaceutical products. The company focuses on building a diverse pipeline of drug candidates targeting critical therapeutic areas, including infectious diseases, various forms of cancer, and vision-impairing degenerative eye conditions. Its key assets include IMT504, an innovative immunotherapy for rabies treatment and vaccine enhancement, and CUBT906, a targeted monoclonal antibody for oncology. Additionally, the company is developing a reformulated Metformin for eye disorders. Curative Biotechnology operates as a development-stage company, meaning its current activities are centered on advancing these candidates through preclinical and clinical stages, aiming for eventual commercialization through internal efforts or strategic partnerships.
What are Curative Biotechnology, Inc.'s primary revenue streams or business model?
As a development-stage biotechnology company, Curative Biotechnology, Inc. currently does not have commercialized products generating significant revenue. Its business model is centered on investing in extensive research and development to discover and advance novel drug candidates through preclinical and clinical trials. Future revenue generation is contingent upon the successful regulatory approval and commercialization of its pipeline assets. This could occur through direct sales if the company builds its own commercial infrastructure, or more likely, through licensing agreements, milestone payments, and royalties from partnerships with larger pharmaceutical companies. The existing co-development partnership for IMT504 exemplifies a strategy to share development costs and potentially future profits.
What are the main risks for CUBT?
Investing in Curative Biotechnology, Inc. carries several significant risks, primarily due to its status as a development-stage biotechnology company and its trading on the 'OTC Other' market. Key risks include the inherent uncertainty and high failure rates associated with clinical trials, where any pipeline candidate could fail to demonstrate efficacy or safety. The company faces substantial capital requirements for its R&D, necessitating future funding rounds that could dilute existing shareholders. Furthermore, its 'OTC Other' listing implies lower liquidity, wider bid-ask spreads, and potential challenges in obtaining comprehensive financial disclosures, leading to higher price volatility and difficulty in accurately assessing its value. Intense competition and lengthy regulatory approval processes also pose considerable threats to its long-term success.
What are the key factors to evaluate for CUBT?
Curative Biotechnology, Inc. (CUBT) holds an AI score of 42/100 (low). Not financial advice.
How frequently does CUBT data refresh on this page?
CUBT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CUBT's recent stock price performance?
Curative Biotechnology, Inc. (CUBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline targeting critical therapeutic areas: infectious diseases, oncology, and degenerative eye conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CUBT overvalued or undervalued right now?
Valuing Curative Biotechnology, Inc. (CUBT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CUBT?
Before investing in Curative Biotechnology, Inc. (CUBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No FMP PEER TICKERS were provided, so competitor information is generalized.
- No analyst ratings or price targets were provided, so the analyst FAQ was omitted as per instructions.
- Specific details on CEO's background and tenure are not provided, so some information is inferred based on company context.
- Disclosure status for OTC is 'Unknown' as per source, which limits detailed analysis of financial reporting.